In a study of adults hospitalized between February 2022 and February 2023, when the omicron variant predominated, monovalent mRNA vaccination was 76% effective at preventing COVID-19-associated invasive mechanical ventilation and death up to 6 months after the last dose and 56% effective at least one year after the last dose, the Centers for Disease Control and Prevention reported. 

The Food and Drug Administration this month authorized using a single dose of bivalent mRNA COVID-19 vaccine for primary vaccination as well as for future doses. The Centers for Disease Control and Prevention recommends all adults remain up to date with COVID-19 vaccination, including the updated bivalent vaccine, to prevent critical outcomes of COVID-19. For the latest AHA resources to promote COVID-19 vaccine confidence, visit www.aha.org/vaccineconfidence
 

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…